Similar articles

• Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.

  Parton M, Gore M, Eisen T. Parton M, et al. J Clin Oncol. 2006 Dec 10;24(35):5584-92. doi: 10.1200/JCO.2006.08.1638. J Clin Oncol. 2006. PMID: 17158544 Review.
• Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen.

  Huland E, Heinzer H. Huland E, et al. Br J Cancer. 2000 Jan;82(1):246-7. doi: 10.1054/bjoc.1999.0952. Br J Cancer. 2000. PMID: 10638997 Free PMC article. Clinical Trial. No abstract available.
• [First-line therapy for German patients with metastatic kidney neoplasms in EORTC-Protocol 30012].

  Rexer H. Rexer H. Urologe A. 2004 Aug;43(8):992-3. doi: 10.1007/s00120-004-0650-2. Urologe A. 2004. PMID: 15316609 German. No abstract available.
• Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.

  Miyake H, Sakai I, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M. Miyake H, et al. Int J Urol. 2009 May;16(5):465-71. doi: 10.1111/j.1442-2042.2009.02262.x. Int J Urol. 2009. PMID: 19467119
• Immunotherapy for metastatic renal cell carcinoma.

  McDermott DF, Rini BI. McDermott DF, et al. BJU Int. 2007 May;99(5 Pt B):1282-8. doi: 10.1111/j.1464-410X.2007.06818.x. BJU Int. 2007. PMID: 17441925 Review. No abstract available.